This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Heritage Cannabis Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Heritage Cannabis Holdings's earnings have been declining at an average annual rate of -30.5%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually. Revenues have been growing at an average rate of 50.5% per year.
Belangrijke informatie
-30.5%
Groei van de winst
-5.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 50.5% |
| Rendement op eigen vermogen | -96.4% |
| Nettomarge | -67.4% |
| Laatste winstupdate | 31 Oct 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Positive Sentiment Still Eludes Heritage Cannabis Holdings Corp. (CSE:CANN) Following 50% Share Price Slump
Mar 27
Positive Sentiment Still Eludes Heritage Cannabis Holdings Corp. (CSE:CANN) Following 33% Share Price Slump
Feb 11Investors Continue Waiting On Sidelines For Heritage Cannabis Holdings Corp. (CSE:CANN)
Dec 18Heritage Cannabis Holdings (CSE:CANN) Has Debt But No Earnings; Should You Worry?
Sep 16Heritage Cannabis Holdings Corp. (CSE:CANN) Looks Inexpensive After Falling 33% But Perhaps Not Attractive Enough
Jul 22Is Heritage Cannabis Holdings (CSE:CANN) Using Too Much Debt?
Jun 15Heritage Cannabis Holdings (CSE:CANN) Is Carrying A Fair Bit Of Debt
Aug 11Is Heritage Cannabis Holdings (CSE:CANN) A Risky Investment?
Aug 24Can You Imagine How Elated Heritage Cannabis Holdings' (CSE:CANN) Shareholders Feel About Its 775% Share Price Gain?
Mar 03Is Heritage Cannabis Holdings (CSE:CANN) Weighed On By Its Debt Load?
Jan 07Opbrengsten en kosten
Hoe Heritage Cannabis Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Oct 23 | 30 | -20 | 16 | 0 |
| 31 Jul 23 | 30 | -33 | 19 | 0 |
| 30 Apr 23 | 29 | -35 | 19 | 0 |
| 31 Jan 23 | 29 | -33 | 17 | 0 |
| 31 Oct 22 | 30 | -24 | 17 | 0 |
| 31 Jul 22 | 26 | -40 | 13 | 0 |
| 30 Apr 22 | 23 | -44 | 14 | 0 |
| 31 Jan 22 | 19 | -48 | 14 | 0 |
| 31 Oct 21 | 14 | -57 | 13 | 0 |
| 31 Jul 21 | 11 | -20 | 11 | 0 |
| 30 Apr 21 | 9 | -13 | 8 | 0 |
| 31 Jan 21 | 6 | -10 | 7 | 0 |
| 31 Oct 20 | 8 | -9 | 6 | 0 |
| 31 Jul 20 | 10 | -4 | 8 | 0 |
| 30 Apr 20 | 8 | -8 | 10 | 0 |
| 31 Jan 20 | 7 | -11 | 11 | 0 |
| 31 Oct 19 | 4 | -13 | 12 | 0 |
| 31 Jul 19 | 0 | -14 | 11 | 0 |
| 30 Apr 19 | 0 | -11 | 9 | 0 |
| 31 Jan 19 | 0 | -8 | 8 | 0 |
| 31 Oct 18 | 0 | -6 | 7 | 0 |
| 31 Jul 18 | 0 | -4 | 6 | 0 |
| 30 Apr 18 | 0 | -3 | 5 | 0 |
| 31 Jan 18 | 0 | -2 | 4 | 0 |
| 31 Oct 17 | 0 | 0 | 2 | 0 |
| 31 Jul 17 | 0 | -2 | 1 | 0 |
| 30 Apr 17 | 0 | -2 | 2 | 0 |
| 31 Jan 17 | 0 | -1 | 1 | 0 |
| 31 Oct 16 | 0 | -1 | 1 | 0 |
| 31 Jul 16 | 0 | -1 | 1 | 0 |
| 30 Apr 16 | 0 | -1 | 1 | 0 |
| 31 Jan 16 | 0 | -1 | 1 | 0 |
| 31 Oct 15 | 0 | -1 | 1 | 0 |
| 31 Jul 15 | 0 | -2 | 1 | 0 |
| 30 Apr 15 | 0 | -2 | 1 | 0 |
| 31 Jan 15 | 0 | -2 | 1 | 0 |
| 31 Oct 14 | 0 | -2 | 1 | 0 |
| 31 Jul 14 | 0 | 0 | 0 | 0 |
| 30 Apr 14 | 0 | 0 | 0 | 0 |
| 31 Jan 14 | 0 | -1 | 0 | 0 |
| 31 Oct 13 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: CANN is currently unprofitable.
Groeiende winstmarge: CANN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CANN is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.
Versnelling van de groei: Unable to compare CANN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CANN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Rendement op eigen vermogen
Hoge ROE: CANN has a negative Return on Equity (-96.37%), as it is currently unprofitable.